This is an open label pre-post study of the effects of clinical treatment with varenicline on
1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in
schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are
assessed on subjective and objective measures of smoking, selected cognitive measures, and
special chemical measures, during baseline testing and during 8 weeks of treatment with
varenicline (1-2 mg/day).